Last reviewed · How we verify
SSRI/Clomipramine
Clomipramine is a tricyclic antidepressant that works by inhibiting the reuptake of serotonin and norepinephrine.
Clomipramine is a tricyclic antidepressant that works by inhibiting the reuptake of serotonin and norepinephrine. Used for Obsessive-compulsive disorder, Major depressive disorder.
At a glance
| Generic name | SSRI/Clomipramine |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | SSRI/SNRI |
| Target | Serotonin transporter, Norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
By blocking the reuptake of these neurotransmitters, clomipramine increases their availability in the synaptic cleft, leading to increased neurotransmission and improved mood. This mechanism is characteristic of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).
Approved indications
- Obsessive-compulsive disorder
- Major depressive disorder
Common side effects
- Dry mouth
- Dizziness
- Constipation
- Fatigue
- Weight gain
Key clinical trials
- Effect of a Family-Based CBT Self-Help Intervention for Adolescents With OCD (NA)
- Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder (NA)
- Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder
- rTMS in Treatment Refractory Obsessive-Compulsive Disorder (NA)
- Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients (PHASE4)
- Treatment of Obsessive Compulsive Disorder in Children (PHASE3)
- Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression (NA)
- Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSRI/Clomipramine CI brief — competitive landscape report
- SSRI/Clomipramine updates RSS · CI watch RSS
- AstraZeneca portfolio CI